Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITE DE FRANCHE COMTE currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BARRON, SEAN C, who is the busiest examiner with 1 pending application. The portfolio's active prosecution is limited to 1 distinct art unit, indicating a focused administrative workload for the company.
Since BARRON, SEAN C is the 1 distinct examiner currently reviewing the company's work, the prosecution success relies on meeting the specific criteria of this official. The 1 to 1 ratio of pending office actions to examiners suggests that the company's immediate patent goals are contained within a single examination path. Practitioners should focus on the 1 pending office action as the sole driver of the company's current patent office interactions.
The concentration in 1 distinct art unit within the Biotechnology & Pharmaceuticals area implies a specific technical application. Successfully navigating the 1 pending application under BARRON, SEAN C is critical for the portfolio's development. This streamlined structure allows the company to dedicate its attention to the feedback provided in the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17641472 | Use of HDL in the prophylaxis of graft-versus-host disease | BARRON, SEAN C | 29d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17641472 | Use of HDL in the prophylaxis of graft-versus-host disease | BARRON, SEAN C | 1653 | §103 | Final Rejection | 29d | Pending | Mar 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial